Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Contraception and safeguarding in abortion care

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Act on immediate danger without removing agency

Threats, sexual violence, trafficking, child exploitation, forced abortion or forced continuation of pregnancy can place the patient at imminent risk during travel, communication, medicine use or discharge.

Action: Consult privately, establish immediate safety, involve named safeguarding and emergency services when necessary, share only information justified by law or serious-harm prevention, and maintain access to the patient's chosen lawful care.

Synopsis

Offer immediate voluntary contraception while identifying reproductive coercion, abuse and exploitation through confidential, proportionate safeguarding that preserves access and autonomy.

  • Ask whether contraception information is wanted and offer the full reversible range on the same day; accepting a method is never a condition for receiving abortion care.
  • Fertility can return rapidly, so methods started at the abortion or within five days generally provide immediate protection under current guidance.
  • An implant can be inserted on the day of surgical abortion or when mifepristone is taken; oral, patch and most other hormonal methods can also start immediately.
  • Insert an intrauterine method at surgical abortion or as soon as possible after medical expulsion when completion is confirmed and infection is not suspected.
  • Intramuscular DMPA may be given with mifepristone, but explain the small possible increase in ongoing-pregnancy risk and ensure completion follow-up.
  • Do not use depot medroxyprogesterone in a patient with current or previous meningioma. Seek expert individualised advice before any hormonal method because tumour type and evidence differ; an implant or another hormonal method may also be inappropriate.
  • Discuss effectiveness, bleeding, side effects, privacy, contraindications, return to fertility and STI protection in a non-directive way that supports the patient's priorities.
  • See every patient alone for part of the assessment and ask about safety, coercion, partner age and power, assault, exploitation and control of reproductive decisions.
  • Confidentiality applies to young people, but share information proportionately when law or serious-harm prevention requires it; explain and document the decision when safe.

Key red flags

An accompanying person answering questions, controlling the phone or medicines, refusing private consultation or threatening consequences suggests coercive control and requires a safe private assessment.

Pregnancy in a child under 13 always requires urgent safeguarding escalation; a marked age or power gap, payment, exploitation, trafficking, assault or a partner in a position of trust also requires an immediate proportionate response.

The patient appears to be forced either to terminate or continue the pregnancy; both are forms of reproductive coercion and can invalidate apparent voluntariness.

A method that can be discovered or controlled by an abusive partner may increase danger, so confidentiality, packaging, records and follow-up contact must be planned explicitly.

Homelessness, unsafe housing, learning disability, language barriers or lack of phone access can make home treatment or later contraception follow-up unsafe without additional support.

Investigation priorities

01
Contraceptive eligibility assessmentFirst step

Identify medical conditions, medicines and preferences that change safe method options.

Management branches

Contraceptive offerTurn preference into same-day access

The patient wants to discuss contraception during abortion care.

  1. Ask about effectiveness, bleeding, hormones, privacy, fertility timing and method control, then check medical eligibility without steering toward long-acting contraception.
  2. Provide the chosen method on the abortion day or at the earliest safe post-expulsion time, using bridging contraception when an intrauterine appointment is delayed.
  3. Explain onset of protection, side effects, completion follow-up, STI prevention and how to switch or remove the method without needing to justify the request.

Key medicines

Etonogestrel contraceptive implantInsert one 68 mg subdermal implant on the day of mifepristone or surgical abortion; the current UK licensed duration is five years.Check enzyme-inducing medicines and insertion eligibility, explain irregular bleeding and palpability, and seek expert advice before use with current or previous meningioma because it may be inappropriate; use safe records and remove promptly when requested.
Depot medroxyprogesterone acetateGive 150 mg by intramuscular injection every 13 weeks; it may start at the mifepristone visit after the specific effectiveness discussion.Contraindicated with current or previous meningioma. Immediate use with mifepristone may slightly raise ongoing-pregnancy risk; discuss bleeding, bone health, repeat timing and delayed return to fertility and ensure abortion completion follow-up.
Open full textbook →Answer 2 questions
Sources and review status9 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG140: Abortion care recommendations
  • NICE QS199: Contraception quality statement
  • Nexplanon 68 mg implant Summary of Product Characteristics
  • Depo-Provera 150 mg/ml Summary of Product Characteristics
  • CoSRH statement: Meningioma and progestogens
  • NHS Specialist Pharmacy Service DMPA intramuscular contraception guidance
  • RCOG: Best practice in post-abortion contraception
  • RCPCH: Safeguarding guidance for under-18 early medical abortion
  • GMC: Contraception, abortion and STI care for young people

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom